BRAIN CANCER

Latest News

April 19th 2018

Everolimus/Chemoradiation Fails to Improve PFS in Newly Diagnosed GBM

Adding everolimus to chemoradiation did not have a significant treatment effect for patients with newly diagnosed glioblastoma, according to results from the phase II NRG Oncology RTOG 0913 trial.

April 17th 2018

Findings With the Antibody Drug Conjugate D3-GPC2-PBD

By Kristopher Bosse, MD

March 21st 2018

The Significance of Brain Metastases in Non-Small Cell Lung Cancer

By Robert C. Doebele, MD, PhD

March 21st 2018

Earlier Pseudoprogression Seen in Patients With Oligodendroglioma Treated With Proton Therapy

By Lisa Astor

March 21st 2018

TTFields with Temozolomide Recommended by NCCN for Newly Diagnosed GBM

By Jason Harris

Latest Videos

Advances in Molecular Testing in Brain Cancer

Results for ABT-414 in Brain Cancer

Wong Discusses New Tumor Treating Fields Technology in Brain Cancer

The Role of Stereotactic Radiosurgery in the Treatment of Brain Metastases

The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade Gliomas

The Status of Biomarker Research in Low-Grade Gliomas

The Various Risk Factors Associated With Glioma

An Overview of the MA17R Trial in Breast Cancer

The Challenges in Using Immune Checkpoint Inhibitors to Treat Patients With Glioblastoma

Impact of Biosimilars on Oncology

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Video

43rd Annual Miami Breast Cancer Conference®

Patrick I. Borgen, MD; Reshma Jagsi, MD, DPhil; Hope S. Rugo, MD, FASCO

Multimedia

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Multimedia

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Multimedia

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Multimedia

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Multimedia

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

In-Person Event

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

May 22, 2026

Register now!

Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Video

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

More News

nmCRPC: Therapy Evolution and Future

March 20th 2018

Clinical Data for Nonmetastatic CRPC

March 20th 2018

Emerging Treatment for nmCRPC

March 20th 2018

nmCRPC: Unmet Needs and Imaging

March 20th 2018

Understanding Nonmetastatic CRPC

March 20th 2018

Changing Treatment Landscape in Nonmetastatic CRPC

March 20th 2018

Prostate Cancer

Evolving Treatment Landscape in Locally Advanced NSCLC

March 20th 2018

Practical Considerations for Durvalumab in Stage 3 NSCLC

March 20th 2018

Locally Advanced NSCLC: Durvalumab and the PACIFIC Trial

March 20th 2018

Unmet Needs and Role of Immunotherapy in Stage 3 NSCLC

March 20th 2018

Chemotherapy Approaches in Locally Advanced NSCLC

March 20th 2018

Locally Advanced NSCLC: Workup and Treatment Approach

March 20th 2018

Immunotherapy in Unresectable Locally Advanced NSCLC

March 20th 2018

Lung Cancer

David Ashley Selected as Director of Duke's Brain Tumor Center

ByDanielle Ternyila

March 13th 2018

David M. Ashley, MBBS, FRACP, PhD, has been named director of the Preston Robert Tisch Brain Tumor Center at Duke University. His position began March 1, 2018, and he succeeded Darell Bigner, MD, PhD.

Future Role of Immunotherapy in NSCLC

March 8th 2018

Dual Checkpoint Inhibition in NSCLC

March 8th 2018

NSCLC: Practical Considerations With Quadruplet Regimen

March 8th 2018

Quadruplet Therapy in NSCLC: IMpower150

March 8th 2018

NSCLC: Immunotherapy Toxicity Management

March 8th 2018

Choosing Among Frontline Options in NSCLC

March 8th 2018

Immunotherapy/Chemo Triplet in Frontline NSCLC

March 8th 2018

Frontline Immunotherapy in PD-L1+ NSCLC

March 8th 2018

Immunotherapy in NSCLC: An Update on Biomarkers

March 8th 2018

Immunotherapy Use in Newly Diagnosed NSCLC

March 8th 2018

Lung Cancer

Cabozantinib Active in Relapsed/Refractory Glioblastoma

ByShannon Connelly

February 21st 2018

In results of a phase II study, cabozantinib (Cabometyx) showed signs of activity in patients with progressive glioblastoma who were naïve to antiangiogenic therapy, despite the predefined statistical target for success not being met.